EMA approves MediWound burns treatment
Market sources believe that Teva will begin marketing the treatment in 2013.
NexoBrid is a gel made of a mixture of enzymes which are extracted from the stem of the pineapple plant. It should be applied topically to a clean burn wound to remove the eschar (the dried-out, thick, leathery, black necrotic tissue that covers severe burn wounds) four hours after the burn. The quick removal of the eschar greatly shortens the recovery time from severe burns.
NexoBrid also reduces the risk of infection of the burn as it includes disinfectants. Four hours after the gel is smeared on the burn, it can be wiped off, exposing the burned area, and thus enabling doctors to determine subsequent treatment.
Clal Biotechnology Industries Ltd. (TASE: CBI) owns 52% of MediWound. Market sources believe that NexoBrid sales will begin in 2013 by Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), which has an option to acquire control of MediWound and a marketing agreement with it.
Published by Globes [online], Israel business news - www.globes-online.com - on September 23, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options